Photo from wikipedia
Glioblastoma multiforme (GBM) is a grade IV astrocytoma, which is the most aggressive form of brain tumor. The standard of care for this disease includes surgery, radiotherapy and temozolomide (TMZ)… Click to show full abstract
Glioblastoma multiforme (GBM) is a grade IV astrocytoma, which is the most aggressive form of brain tumor. The standard of care for this disease includes surgery, radiotherapy and temozolomide (TMZ) chemotherapy. Poor accumulation of TMZ at the tumor site, tumor resistance to drug and dose-limiting bone marrow toxicity eventually reduce the success of this treatment. Herein, we have encapsulated > 500 drug molecules of TMZ into the biocompatible protein nanocage, apoferritin (AFt), using a 'nanoreactor' method (AFt-TMZ). AFt is internalized by transferrin receptor 1-mediated endocytosis and is therefore able to facilitate cancer cell-uptake and enhance drug efficacy. Following encapsulation, the protein cage retained its morphological integrity and surface charge, hence its cellular recognition and uptake are not affected by the presence of this cargo. Additional benefits of AFt include maintenance of TMZ stability at pH 5.5 and drug release under acidic pH conditions, encountered in lysosomal compartments. MTT assays revealed that the encapsulated agents displayed significantly increased anti-tumor activity in U373V (vector control) and, remarkably the isogenic, U373M (MGMT expressing TMZ-resistant) GBM cell lines, with GI50 values < 1.5 μM for AFt-TMZ, compared to 35 μM and 376 µM for unencapsulated TMZ against U373V and U373M, respectively. The enhanced potency of AFt-TMZ was further substantiated by clonogenic assays. Potentiated G2/M cell cycle arrest following exposure of cells to AFt-TMZ indicated an enhanced DNA damage burden. Indeed, increased O6-methylguanine (O6-MeG) adducts in cells exposed to AFt-TMZ and subsequent generation of γH2AX foci, support the hypothesis that AFt significantly enhances the delivery of TMZ to cancer cells in vitro; overwhelming the direct O6-MeG repair conferred by MGMT. We have additionally encapsulated > 500 molecules of the N3-propargyl imidazotetrazine analog (N3P), developed to combat TMZ resistance, and demonstrated significantly enhanced activity of AFt-N3P against GBM and colorectal carcinoma cell lines. These studies support the use of AFt as a promising nano-delivery system for targeted delivery, lysosomal drug release and enhanced imidazotetrazine potency for treatment of GBM and wider-spectrum malignancies.